Cantai Therapeutics Overview
- Year Founded
-
2023
- Status
-
Private
- Employees
-
5
- Latest Deal Type
-
Early Stage VC
- Latest Deal Amount
-
$3.55M
- Investors
-
3
Cantai Therapeutics General Information
Description
Operator of a therapeutics company intended to advance next-generation bispecific antibodies for autoimmune diseases. The company focuses on treating autoimmune and inflammatory disorders by developing cytokine-targeting, enabling patients suffering from immune-mediated and autoimmune diseases to receive effective treatments.
Contact Information
Website
www.cantaitx.comCorporate Office
- 3675 Market Street
- Suite 200
- Philadelphia, PA 19104
- United States
Corporate Office
- 3675 Market Street
- Suite 200
- Philadelphia, PA 19104
- United States
Cantai Therapeutics Timeline
Cantai Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Early Stage VC | 21-Jan-2026 | $3.55M | Completed | Startup | ||
| 1. Seed Round | 20-Nov-2023 | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Cantai Therapeutics Patents
Cantai Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026151915-A1 | Il-23 binding antibodies and methods of use | Pending | 09-Jan-2025 | ||
| WO-2026064545-A1 | Engineered tl1a targeting regions and methods of use | Pending | 19-Sep-2024 | ||
| EP-4812501-A1 | Engineered bispecific molecules and methods of use | Pending | 22-Nov-2023 | ||
| US-20260265389-A1 | Engineered bispecific molecules and methods of use | Pending | 22-Nov-2023 | ||
| WO-2025111585-A1 | Engineered bispecific molecules and methods of use | Inactive | 22-Nov-2023 | C07K16/2875 |
Cantai Therapeutics Signals
Cantai Therapeutics Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Agent Capital | Venture Capital | Minority | ||
| Alloy Therapeutics | VC-Backed Company | Minority | ||
| Tellus BioVentures | Venture Capital | Minority |
Cantai Therapeutics FAQs
-
When was Cantai Therapeutics founded?
Cantai Therapeutics was founded in 2023.
-
Where is Cantai Therapeutics headquartered?
Cantai Therapeutics is headquartered in Philadelphia, PA.
-
What is the size of Cantai Therapeutics?
Cantai Therapeutics has 5 total employees.
-
What industry is Cantai Therapeutics in?
Cantai Therapeutics’s primary industry is Drug Discovery.
-
Is Cantai Therapeutics a private or public company?
Cantai Therapeutics is a Private company.
-
What is Cantai Therapeutics’s current revenue?
The current revenue for Cantai Therapeutics is .
-
How much funding has Cantai Therapeutics raised over time?
Cantai Therapeutics has raised $6.55M.
-
Who are Cantai Therapeutics’s investors?
Agent Capital, Alloy Therapeutics, and Tellus BioVentures have invested in Cantai Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process